Mechanisms of Immune Dysfunction in Renal Cell Carcinoma

  • Ithaar H. Derweesh
  • Charles S. Tannenbaum
  • Patricia A. Rayman
  • James H. Finke
Part of the Cancer Treatment and Research book series (CTAR, volume 116)

Abstract

The immunologic control of carcinogenesis was first demonstrated by Gross in 1943,1 who made the observation that inbred mice could be immunized against tumor transplants from syngeneic animals. In 1970, the concept of “immune surveillance” was developed by Burnet2,who proposed that cancers express unique antigens that would allow their detection by the host’s immune system. Subsequent discovery of T cell subsets, TCR complex, antigen presentation, MHC restriction and molecular approaches to identify antigens have contributed to our understanding of T cell immunity to tumors

Keywords

Lymphoma Shrinkage Oncol Sarcoma Oligomerization 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gross L. Intradermal immunization of G3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3:326–333,1943Google Scholar
  2. 2.
    Burnet M. Immunologic surveillance. Oxford: Pergamon press, 1970Google Scholar
  3. 3.
    Altman A, Cogeshall K, and Mustelin T. Molecular events mediating T cell activation. Adv. Immunol. 48:227–360,1990Google Scholar
  4. 4.
    Foss FM. Immunologic mechanisms of antitumor activity. Semin. Oncol. 29(3 Suppl 7):5–11,2002Google Scholar
  5. 5.
    Lucey DR, Clerici M, and Shearer GM. Type I and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin. Microbiol. Rev. 9:532–562,1996Google Scholar
  6. 6.
    Ullman KS, Northrop JP, Verweij CL, and Crabtree GR. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu. Rev. Immunol 8:421–452,1990PubMedCrossRefGoogle Scholar
  7. 7.
    Singer AL, and Koretzky GA. Control of T cell function by positive and negative regulators. Science. 296:1639–1640,2002PubMedCrossRefGoogle Scholar
  8. 8.
    Montie JE, Stewart BH, Straffon RA, et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol. 117:272–275,1977PubMedGoogle Scholar
  9. 9.
    Mountain CF, Khalil KG, Hermes KE, and Frazier OH. The contribution of surgery to the management of carcinomatous pulmonary metastases. Cancer 41:833–840,1978PubMedCrossRefGoogle Scholar
  10. 10.
    Yron I, Wood TA, Spiess P, and Rosenberg SA. In vitro growth of murine T cells: V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J. Immunol 125:238–245,1980PubMedGoogle Scholar
  11. 11.
    Rosenberg SA. Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine-activated killer cells. In Devita VT, Hellman S, and Rosenberg SA, eds. Important advances in Oncology 1988. Philadelphia, P. Lippincott. Company. 217–257,1988Google Scholar
  12. 12.
    Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA. 271:907–913, 1994PubMedCrossRefGoogle Scholar
  13. 13.
    Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, and Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin2 therapy. J. Clin. Oncol. 13:688–696,1995PubMedGoogle Scholar
  14. 14.
    Bahceci E, Read EJ, Leitman S, Childs R, Dunbar C, Young NS, and Barrett J. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical hematopoietic stem cell transplantation (HSCT) for hematological malignancies. Br. J. Haematol. 108:404–414, 2000CrossRefGoogle Scholar
  15. 15.
    Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read Ej, Tisdale J, Dunbar C, Linehan WM,Young NS, and Barrett AI Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Eng. J. Med. 343:750–758, 2000CrossRefGoogle Scholar
  16. 16.
    Neumann E, Engelberg A, Decker J, Storkel S, Jaeger E, Huber C, and Seliger B. Heterogeneous espression of the tumor-associated antigens RAGE, PRAME, and Glycoprotein 75 in human renal cell carcinoma; candidates for T-cell–based immunotherapy. Cancer Res. 58:4090–4095,1998PubMedGoogle Scholar
  17. 17.
    Finke JH, Rayman P, Hart L, Alexander JP, Edinger MG, Tubbs RR, et al. Characterization of TIL subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity IFNy secretion and proliferation. J. Immunother. 15:91–104,1994CrossRefGoogle Scholar
  18. 18.
    Alexander P, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM, et al. T-cell infiltrating renal cell carcinoma display a poor proliferative response even though they can produce IL-2 and express IL2 receptors, Cancer Res. 53:1380–1387,1993PubMedGoogle Scholar
  19. 19.
    Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V, Joyeus I, et al. Variable expression of CD3- y chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function, Int. J. Cancer. 63:205–212,1995PubMedCrossRefGoogle Scholar
  20. 20.
    Finke J, Ferrone S, Frey A, Mufson A, and Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol. Today. 20:158–160,1999Google Scholar
  21. 21.
    Finke JH, Tubbs R, Connelly B, Pontes E, and Montie J. Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann. N.Y. Acad. Sci. 532:387–394,1988PubMedCrossRefGoogle Scholar
  22. 22.
    Belldegrun A, Muul LM, and Rosenberg SA. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res. 48:206–214,1988PubMedGoogle Scholar
  23. 23.
    Schendel DJ, Oberneder R, Falk CS, Jantzer P, Kressenstein S, Maget B, Hofstetter A, Riethmuller G, and Nossner E. Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J. Mol. Med. 75:400–413,1997PubMedCrossRefGoogle Scholar
  24. 24.
    Nakagomi H, Pisa P, Pisa EK,Yamamoto Y, Halapi E, Backlin K, Juhlin C, and Kiessling R. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int. J. Cancer. 63:366–371, 1995PubMedCrossRefGoogle Scholar
  25. 25.
    Wang Q, Redovan C, Tubbs R, Olencki T, Klein E, Kudoh S, Finke J, and Bukowski RM. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int. J. Cancer. 61:780–785, 1995PubMedCrossRefGoogle Scholar
  26. 26.
    Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, Gerdin B, and Kiessling R. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc. Natl. Acad. Sci. USA 89:7708–7712, 1992PubMedCrossRefGoogle Scholar
  27. 27.
    Cardi G, Mastrangelo ML, and Beard D. Deletion of T cells with the CD4+ CD45R+ phenotype in lymphocytes that infiltrate subcutaneous metastases of human melanoma. Cancer Res. 49:6562–6565, 1989PubMedGoogle Scholar
  28. 28.
    Miescher S, Whiteside TL, Moretta L, and von Fliendner V. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J. Immunol 138:4004–4011, 1987PubMedGoogle Scholar
  29. 29.
    Rayman P, Uzzo RG, Kolenko V, Bloom T, Cathcart MK, Molto L, Novick AC, Bukowski RM, Hamilton T, and Finke JH. Tumor-induced dysfunction in interleukin-2 production and interleukin2 receptor signaling: a mechanism of immune escape. Cancer J. Sci. Am. 6:S81–S87, 2000Google Scholar
  30. 30.
    Kudoh S, Redovan C, Rayman P, Edinger M, Tubbs RR, Novick A, Finke JH, and Bukowski RM. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. J. Immunother. 20:479–487, 1997PubMedCrossRefGoogle Scholar
  31. 31.
    Klugo RC. Diagnostic and therapeutic immunology of renal cell cancer. Henry Ford Med. J. 27:106–109, 1979Google Scholar
  32. 32.
    Amano T, Koshida K, Nakajima K, Nato K, and Hisazums H. PPD, PHA and SU-PS skin test in genitourinary malignancies. Acta. Urologica. Japonica. 31:2107–2111, 1985Google Scholar
  33. 33.
    Bernhard H, Karbach J, Wolfel T, Busch P, Storkel S, Stockle M, Wolfel C, Seliger B, Huber C, Mayer zum Buschenfelde KH, et al. Cellular immune response to human renal-cell carcinomas: defmition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones. Int. J. Cancer. 59:837–842, 1994PubMedCrossRefGoogle Scholar
  34. 34.
    Finke JH, Rayman P, Edinger M, Tubbs RR, Stganley J, Klein E, and Bukowski R. Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell Rine. J. Immunother. 11:1–11, 1992PubMedCrossRefGoogle Scholar
  35. 35.
    van Endert PM. Genes regulating MHC class I processing of antigen. Curr. Opin. Immunol. 11:82–88, 1999PubMedCrossRefGoogle Scholar
  36. 36.
    Seliger B, Maeurer MJ, and Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today. 21:455–464, 2000PubMedCrossRefGoogle Scholar
  37. 37.
    Seliger B, Hammers S, Hohne A, Zeidler R, Knuth A, Gerharz CD, and Huber C. IFN-gammamediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin. Cancer. Res. 3:573–578, 1997Google Scholar
  38. 38.
    Seliger B, Hohne A, Jung D, Kallfelz M, Knuth A, Jaeger E, et al. Expression and function of the peptide transporters in escape variants of human renal cell carcionomas. Exper. Hematol. 25:608–61 4, 1997Google Scholar
  39. 39.
    Seliger B, Hohne A, Knuth A, Bernhard H, Meyer T, Tampe R, Momburg F, and Huber C. Analysis of the major histocompatibility class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res. 56:1756–1760, 1996PubMedGoogle Scholar
  40. 40.
    Kallfelz M, Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, and Seliger B. Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP]-gene transfer. Int. J. Cancer. 81:125–133, 1999Google Scholar
  41. 41.
    Steinman RM. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. 9:271–296, 1991CrossRefGoogle Scholar
  42. 42.
    Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 90:3245–3287, 1997PubMedGoogle Scholar
  43. 43.
    Scheicher C, Mehlig M, Dienes H, and Reske K. Uptake of microparticle-adsorbed protein antigen by bone marrow-derived dendritic cells results in upregulation of interleukin-I a and interleukin12 p40/p35 and triggers prolonged, efficient antigen presentation. Eur. J. Immunol 25:1566–1572, 1995PubMedCrossRefGoogle Scholar
  44. 44.
    Larsen CP, Ritchie SC, Hendrix R, Linsley PS, Hathcock KS, Hodes RJ, Lowry RP, and Pearson TC. Regulation of immunostimulatory function and costimulatory molecule (B7.1 and B7.2) expression on murine dendritic cells. J. Immunol. 152:5208–5219, 1994PubMedGoogle Scholar
  45. 45.
    Zhou L, and Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily J. Immunol 154:3821–3835, 1995Google Scholar
  46. 46.
    Austyn JM. The dendritic cell system and anti-tumor immunity. In Vivo. 7:193–201, 1993PubMedGoogle Scholar
  47. 47.
    Buelens C, Willems F, Delvaux A, Pierard G, Delville JP, Velu T, and Goldman M, Interleuldn-10 differentially regulates B7–1 (CD80) and B7–2 (CD86) expression on human peripheral blood dendritic cells. Eur. J. Immunol. 25:2668, 1995PubMedCrossRefGoogle Scholar
  48. 48.
    Nomori H. Histiocytes in nasopharyngeal carcinoma in relation to prognosis. Cancer. 57:100, 1986PubMedCrossRefGoogle Scholar
  49. 49.
    Nakano T, Oka K, Arai T, Morita S, and Tsuremoto H. Prognostic significance of Langerhans cell infiltration in radiation therapy for squamous cell carcinoma of the uterine cervix. Arch. Pathol. Lab. Med. 113:507, 1989PubMedGoogle Scholar
  50. 50.
    Chaux P, Moutet M, Faivre J, Martin F, and Martin, M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7–1 and B7–2 costimulatory molecules of the T-cell activation. Lab. Invest. 74:975, 1996Google Scholar
  51. 51.
    Thurnher M, Radmayr C, Ramoner R, Ebner S, Bock G, Klocker H, Romani N, and Bartsch G. Human renal cell carcinoma tissue contains dendritic cells. Int. J. Cancer. 67:1, 1996CrossRefGoogle Scholar
  52. 52.
    Troy AJ, Summers KL, Davidson PI Atkinson CH, and Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer. Res. 4:585–593, 1998Google Scholar
  53. 53.
    Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, Blay JY. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin6 and macrophage colony-stimulating factor. Blood. 92:4778–4791, 1998PubMedGoogle Scholar
  54. 54.
    Schwartz RH. T cell clonal anergy. Curt Opin. Immunol 9351–357, 1997Google Scholar
  55. 55.
    Mondino A, Khoruts A, and Jenkins MC. The anatomy of T-cell activation and tolerence. Proc. Natl. Acad. Sci. USA. 93:2245–2252, 1996PubMedCrossRefGoogle Scholar
  56. 56.
    Appleman LJ, Tzachani D, Grader-Beck T, van Puijenbroek AAFL, and Boussiotis VA. Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics. J. Mol. Med. 78:673–683, 2001PubMedCrossRefGoogle Scholar
  57. 57.
    Staveley-O’Carroll K, Sotomayor E, Montgomery J, Borello I, Hwang L, Fein S, Pardoll D, and Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA. 95:1178–1183, 1998PubMedCrossRefGoogle Scholar
  58. 58.
    Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, and Marincola FM. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol 163:6867–6875, 1999PubMedGoogle Scholar
  59. 59.
    Nielsen M-B, and Marincola FM. Melanoma vaccines: the paradox of T cell activation without clinical response. Cancer Chemother Pharmacol. 46:S62–S66, 2000PubMedCrossRefGoogle Scholar
  60. 60.
    Boussiotis VA, McArthur JG, Gribben JG, and Nadler LM. The role of B7–1 /B7–2:CD28/ CTLA-4 pathways in the prevention of anergy, induction of production immunity and down-regulation of the immune response. Immunol Rev. 153:5–26, 1996PubMedCrossRefGoogle Scholar
  61. 61.
    Sotomayor EM, Borello I, Tubb E, Rattis F-M, Bien, Lu Z, Fein S, Schoenberger S, and Levitsky HI. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nature Medicine. 5:780–787, 1999PubMedCrossRefGoogle Scholar
  62. 62.
    Ohlen C, Kalos M, Hong DJ, Shur, AC, and Greenberg PD. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8’ T Cells or CTL immunotherapy of tumors expressing the antigen. J. Immunol. 166:2863–2870, 2001PubMedGoogle Scholar
  63. 63.
    Welsh RM. Assessing CD8 T Cell number and dysfunction in the presence of antigen J. Exp. Med. 193:19–22, 2001CrossRefGoogle Scholar
  64. 64.
    Wittke F, Hoffmann R, Buer J, Dallmann I, Oevermann K, Sel S, Wandert T, Ganser A, and Atzpodien J. Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br. J. Cancer. 79:1182–1184, 1999PubMedCrossRefGoogle Scholar
  65. 65.
    Akdis CA, and Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology. 103:131–136, 2001PubMedCrossRefGoogle Scholar
  66. 66.
    Olive C, Cheung C, Nicol D, and Falk MC. Expression of cytokine mRNA transcripts in renal cell carcinoma. Immunol Cell. Biol. 76:357–362, 1998PubMedCrossRefGoogle Scholar
  67. 67.
    Onishi T, Onishi Y, Goto H, Tomita M, and Abe K. An assessment of the immunological status of patients with renal cell carcinoma based on the relative abundance of T-helper 1- and -2 cytokineproducing CD4+ cells in peripheral blood. BJU. Int. 87:755–759, 2001Google Scholar
  68. 68.
    Ochoa AC, and Longo DL. Alteration of signal transduction in T cells from cancer patients. In Important Adv. Oncol., Devita VD, Hellman S, and Rosenberg SA, eds., JB. Lipponcott, Philadelphia. 43–54, 1995Google Scholar
  69. 69.
    Chan AC, Irving BA, and Weiss A. New insights into T-cell antigen receptor structure and signal transduction. Curt Opin. Immunol 4:246–252,1992CrossRefGoogle Scholar
  70. 70.
    Bukowski RM, Rayman P, Uzzo R, Bloom T, Sandstrom K, Peereboom D, Olencki T, Budd GT, Mclain D, Elson P, Novick A, and Finke JH. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: Clinical relevance and effects of cytokine therapy. Clin. Canc. Res. 4:2337–2347,1998Google Scholar
  71. 71.
    Cardi G, Heaney JA, Schned AR, Phillips DM, Branda MT, and Ernstoff MS. T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma. Cancer Res. 57:3517–3519, 1997PubMedGoogle Scholar
  72. 72.
    Kono K, Ressing ME, Brandt RMP, Melief CJM, Potkul RK, Andersson B, Petersson M, Kast WM, and Kiessling R. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin. Cancer Res. 2:1825–1828,1996Google Scholar
  73. 73.
    Frydecka I, Kaczmarek P, Bocko D, Kosmaczewska A, Morilla R, and Catovsky D. Expression of signal-transducing zeta chain in peripheral blood T cels and natural killer cells in patients with Hodgkin’s disease in different phases of the disease. Leuk. Lymphoma. 35:545–554, 1999CrossRefGoogle Scholar
  74. 74.
    Reichert TE, Day R, Wagner EM, and Whiteside TL. Absent or low expression of the s chain in T cells at the tumor site correlates with poor surival in patients with oral carcinoma. Cancer Res. 58:5344–5347,1998PubMedGoogle Scholar
  75. 75.
    Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheilbenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, and Atkins MB. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the society for biological therapy. J. Immunother. 25:97–138, 2002PubMedCrossRefGoogle Scholar
  76. 76.
    Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, and Kiessling R. Hydrogen peroxide secreted by tumor-specific T-cell and natural killer cell-mediated cytotoxicity. Eur. J. Immunol 26:1308–1313,1996PubMedCrossRefGoogle Scholar
  77. 77.
    Schmielau J, and Finn OJ. Activated granulocytes and gralulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-Cell Function in Advanced Cancer Patients. Cancer Res. 61:4756–4760, 2001PubMedGoogle Scholar
  78. 78.
    Gasman BR, Johnson DE, Whiteside TL, and Rabinowich H. Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res. 59:1422–1427,1999Google Scholar
  79. 79.
    Gasman BR, Johnson DE, Whiteside TL, Rabinowich H. Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood. 95:2015–2023, 2000Google Scholar
  80. 80.
    Saito T, Dworacki G, Gooding W, Lotze MT, and Whiteside TL. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin. Cancer Res. 6: 1351–1364,2000PubMedGoogle Scholar
  81. 81.
    Takahashi A, Kono K, Amemiya H, Iizuka H, Fujii H, and Matsumoto Y. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and down-regulation of TCR zeta molecules in patients with gastric cancer. Clin. Cancer Res. 7:74–80, 2001Google Scholar
  82. 82.
    Isomaki P, Panesar M, Annenkov A, Clark JM, Foxwell BMJ, Chernajjovsky Y, and Cope AR. Prolonged exposure of T cells to TNF down-regulates TCRz and expression of the TCR/CD3 complex at the cell surface. J. Immunol 166:5495–5507,2001PubMedGoogle Scholar
  83. 83.
    Taheri F, Ochoa JB, Faghiri Z, Culotta K, Park H-J, Lan MS, Zea AH, and Ochoa AC. L-arginine regulates the expression of the T-cell receptor z chain (CD3z) in Jurkat Cells. Clin. Cancer Res. 7:765s-958s, 2001Google Scholar
  84. 84.
    Morford LA, Elliott LH, Carlson SL, Brooks WH, and Roszman TL. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J. Immunol. 159:4415–4425,1997PubMedGoogle Scholar
  85. 85.
    Rayet B, and Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 18:6938–6947,1999PubMedCrossRefGoogle Scholar
  86. 86.
    Ng CS, Novick AC, Tannenbaum CS, Bukowski RM, and Finke JH. Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression. Urology. 59:9–14,2002PubMedCrossRefGoogle Scholar
  87. 87.
    Gati A, Guerra N, Giron-Michel J, Azzarone B, Angevin E, Moretta A, Chouaib S, and Caignard A. Tumor cells regulate the lytic activity of tumor-specific cytotoxic T lymphocytes by modulating the inhibitory natural killer receptor function. Cancer Res. 61:3240–3244, 2001PubMedGoogle Scholar
  88. 88.
    Ghosh P, Komschilies KL, Cippitelli M, Longo DL, Subleski J, Ye J, Sica A, Young HA, Wiltrout RH, and Ochoa AC. Gradual loss of T-Helper I populations in spleen of mice during progressive tumor growth. J. Nat. Cancer Inst. 87:1478–1483,1995CrossRefGoogle Scholar
  89. 89.
    Uzzo RG, Rayman P, Klenko V, Clark PE, Cathcart MK, Bloom T, Novick AC, Bukowski RM, Hamilton T, and Finke JH. Renal cell carcinoma-derived gangliosides suppress nuclear factor-KB activation in T cells. J. Clin. Invest. 104:769–776, 1999CrossRefGoogle Scholar
  90. 90.
    Uzzo RG, Clark PE, Rayman P, Bloom T, Rybicki L, Novick AC, Bukowski RM, and Finke JH, Alterations in NFxB activation in T Lymphocytes of Patients with renal cell carcinoma. J. Nat. Cancer Ins. 91:718–721,1999(b)CrossRefGoogle Scholar
  91. 91.
    Hatada EN, Krappmann D, and Scheidereit C. NF-kappaB and the innate immune response. Curt Opin. Immunol. 12:52–58, 2000Google Scholar
  92. 92.
    Aronica MA, Mora A, Mitchell DB, Finn PW, Johnson JE, Sheller JR, and Boothby MR. Preferential role for NF-xB/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo. J. Immunol. 163:5116–5124,1999PubMedGoogle Scholar
  93. 93.
    Malmberg K-J, Arulampalam V, Ichihara F, Petersson M, Seki K, Andersson, T, Lenkei R, Masucci G, Pettersson S, and Kiessling R. Inhibition of activated/memory (CD45RO+) T cells by oxidative stress associated with block of NFKB activation. J. Immunol. 167:2592–2601, 2001Google Scholar
  94. 94.
    Guerder S, Rincon M, and Schmitt-Verhults A-M. Regulation of activator protein-1 and NF-KB in CD8’ T cells exposed to peripheral self-antigens. J. Immunol 166:4399–4407,2001PubMedGoogle Scholar
  95. 95.
    Finke JH, Rayman P, George R, Tannenbaum CS, Kolenko V, Uzzo R, Novick AC, and Bukowski RM. Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression. Clin. Cancer Res. 7(3 Suppl):940s-946s, 2001PubMedGoogle Scholar
  96. 96.
    Bloom BR, Salgame P, and Diamond B. Revisiting and revising suppressor T cells. Immunol Today. 13:131–136, 1992PubMedCrossRefGoogle Scholar
  97. 97.
    Clerici M, and Shearer GM. The TH1/TH2 hypothesis of HIV infection: new insights. Immunol. Today. 15:575–581, 1994Google Scholar
  98. 98.
    Yoneda Y, and Yoshida R. The role of T cells in allografted tumor rejection: IFN-gamma released from T cells is essential for induction of effector macrophages in the rejection site. J. Immunol. 160:6012–6017, 1998PubMedGoogle Scholar
  99. 99.
    Kemp RA, and Ronchese F. Tumor-specific Tcl, but not Tc2, cells deliver protective antitumor immunity. J. Immunol 167:6497–6502, 2001PubMedGoogle Scholar
  100. 100.
    Hu MM, Urba WJ, and Fox BA. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J. Immunol 15:3033–3341, 1998Google Scholar
  101. 101.
    Goto S, Sato M, Kaneko R, Itoh M, Sato S, and Takeuchi S. Analysis of Thl and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol. Immunother. 48:435–442, 1999CrossRefGoogle Scholar
  102. 102.
    Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, and Rodeck U. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am. J. Pathol. 155:537–547, 1999PubMedCrossRefGoogle Scholar
  103. 103.
    Maeda H, and Shiraishi A. TGF-beta contributes to the shift toward TH2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol 156:73–78, 1996PubMedGoogle Scholar
  104. 104.
    Ortegel JW, Staren ED, Faber LP, Warren WH, and Braun DR Modulation of tumor-infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer. Lung. Cancer. 36:17–25, 2002PubMedCrossRefGoogle Scholar
  105. 105.
    Cottrez F, and Groux H. Regulation of TGF-beta response during T cell activation is modulated by IL-10. J. Immunol 167:773–778, 2001PubMedGoogle Scholar
  106. 106.
    Adris S, Klein S, Jasnis M, Chuluyan E, Ledda M, Bravo A, Carbone C, Chernajovsky Y, and Podhajcer O. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response. Gene Ther. 6:1705–1712,1999PubMedCrossRefGoogle Scholar
  107. 107.
    Huang S, Ullrich SE, and Bar-Eli M. Regulation of tumor growth and metastasis by interleukin10: the melanoma experience. J. Interferon. Cytokine. Res. 19:697–703, 1999PubMedCrossRefGoogle Scholar
  108. 108.
    Groux H, Cottrez F, Rouleau M, Mauze S, Antonenko S, Hurst S, McNeil T, Bigler M, Roncarolo MG, and Coffman RL. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J. Immunol 162:1723–1729, 1999PubMedGoogle Scholar
  109. 109.
    Ribas A, Butterfield LH, Hu B, Dissette VB, Meng WS, Koh A, Andres KJ, Lee M, Amu SN, Glaspy JA, McBride WH, and Economou JS. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. Cancer Res. 60:2218–2224, 2000PubMedGoogle Scholar
  110. 110.
    Muschen M, Moers C, Warskulat U, Even J, Niederacher D, and Beckmann MW. CD95 Ligand expression as a mechanism of immune escape in breast cancer. Immunology. 99:69–77, 2000PubMedCrossRefGoogle Scholar
  111. 111.
    Black PH. Shedding from the cell surface of normal and cancer cells. Adv. Cancer Res. 32:75–199, 1980PubMedCrossRefGoogle Scholar
  112. 112.
    Hakomori S. Tumor-associated carbohydrate antigens. Annu. Rev. Immunol. 2:103–126, 1984CrossRefGoogle Scholar
  113. 113.
    Hoon DS, Okun E, Neuwirth H, Morton DL, and Inci RE Aberrant expression of gangliosides in human renal cell carcinomas. J. Urol. 150:2013–2018, 1993PubMedGoogle Scholar
  114. 114.
    Ladisch S, Gillard B, and Wong C. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res. 43:3808, 1983PubMedGoogle Scholar
  115. 115.
    Skipski VP, Katopodis N, Prendergast JS, and Stock CC. Gangliosides in blood serum of normal rats and Morris hepatoma 5123tc-bearing rats. Biochem. Biophys. Res. Commun. 67:1122–1127, 1975Google Scholar
  116. 116.
    Kloppel TM, Keenan TW, Freeman MJ, and Morre DJ. Glycolipid-bound sialic acid in serum: increased levels in mice and humans bearing mammary carcinomas. Proc. Natl. Acad. Sci. USA 74:3011, 1977PubMedCrossRefGoogle Scholar
  117. 117.
    Li R, and Ladisch S. Shedding of human neuroblastoma gangliosides. Biochim. Biophys. Acta. 1083:57–64, 1991CrossRefGoogle Scholar
  118. 118.
    Heitger A, and Ladisch S. Gangliosides block antigen presentation by human monocytes. Biochim. Biophy. Acta. 1303:161–168, 1996CrossRefGoogle Scholar
  119. 119.
    Miller HC, and Esselman WJ. Modulation of the immune response by antigen reactive lymphocytes after cultivation with gangliosides. J. Immunol 115:839–843, 1975PubMedGoogle Scholar
  120. 120.
    Lu P, and Sharom FJ. Immunosuppression by YAC-1 lymphoma: role of shed gangliosides. Cell Immunol 173:22–32, 1996PubMedCrossRefGoogle Scholar
  121. 121.
    Sharom FJ, Chiu AL, and Chu JW. Membrane gangliosides modulate interleukin-2-stimulated T-lymphocyte proliferation. Biochim. Biophys. Acta. 1094:35–42, 1991Google Scholar
  122. 122.
    Garofalo T, Sorice M, Misasi R, Cinque B, Giammatteo M, Pontieri GM, Cifone MG, and Pavan A. A novel mechanism of CD4 down-modulation induced by monosialoganglioside GM3: involvement of serine phosphorylation and protein kinase Cd translocation. J. Biol. Chem. 273: 35153–35160,1998PubMedCrossRefGoogle Scholar
  123. 123.
    Grayson G, and Ladisch S. Immunosuppression by human gangliosides. II. Carbohydrate structure and inhibition of human NK activity. Cell Immunol. 139:18–29, 1992PubMedCrossRefGoogle Scholar
  124. 124.
    Irani DN. Brain-derived gangliosides induce cell cycle arrest in a murine T cell line. J. Neuroimmunol. 87:11–16, 1998PubMedCrossRefGoogle Scholar
  125. 125.
    Kanda N. Gangliosides GDla and GM3 induce interleukin-10 production by human T cells. Biochem. Biophys. Res. Commun. 256:41–44, 1999Google Scholar
  126. 126.
    Estaquier J, and Ameisen JC. A role for T-helper type-1 and type-2 cytokines in the regulation of human monocyte apoptosis. Blood. 90:1618–1625, 1997PubMedGoogle Scholar
  127. 127.
    Dhein J, Walczak H, Baumler C, Debatin KM, and Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 373:438–441, 1995PubMedCrossRefGoogle Scholar
  128. 128.
    Radoja S, Saio M, and Frey AB. CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ. J. Immunol 166:6074–6083,2001PubMedGoogle Scholar
  129. 129.
    Uzzo RG, Rayman P, Kolenko V, Ckarj OE, Bloom T, Ward AM, Molto L, Tannenbaum C,Worford LJ, Bukowski R, Tubbs R, Hsi ED, Bander NH, Novick AC, and Finke JH. Mechanisms of Apoptosis in T cells from patients with renal cell carcinoma. Clin. Cancer Res. 5:1219–1229,1999Google Scholar
  130. 130.
    Nunez G, Benedict MA, Hu Y, and Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene. 17:3237–3245, 1998PubMedCrossRefGoogle Scholar
  131. 131.
    Boldin MP, Goncharov TM, Goltsev YV, and Wallach D. Involvement ofMACH, a novel MORT1/FADD-interacting protease, in Fas/AP0–1-and TNF receptor-induced cell death. Cell, 85:803–815, 1996PubMedCrossRefGoogle Scholar
  132. 132.
    Nagata S. Apoptosis by death factor. Cell. 88:355–365, 1997PubMedCrossRefGoogle Scholar
  133. 133.
    Ashkenazi A, and Dixit VM. Death receptors: Signaling and modulation. Science. 281:1305–1308, 1998PubMedCrossRefGoogle Scholar
  134. 134.
    Hirata H, Takahashi A, Kobayashi S, Yonebara S, Sawai H, Okazaki T, Yamamoto K, and Sasada M. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J. Exp. Med. 187:587–600, 1998PubMedCrossRefGoogle Scholar
  135. 135.
    Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, and Wang X. Cytochrome c and dATP-dependent formation of Apaf-1 /caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:479–489, 1997PubMedCrossRefGoogle Scholar
  136. 136.
    Zou H, Henzel WJ, Liu X, Lutschg A, and Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 90:405–413, 1997PubMedCrossRefGoogle Scholar
  137. 137.
    Yang J, Liu XS, Bhalla K, Kim CN, Ibrado AM, Cai jY, Peng TI, Jones DP, and Wang XD. Prevention of apoptosis by Bc12: release of cytochrome c from mitochondria blocked. Science. 275:1129–1132,1997PubMedCrossRefGoogle Scholar
  138. 138.
    Kluck RM, Bossywetzel E, Green DR, and Newmeyer DD. The release of cytochrome c from mitochondria-a primary site for Bcl-2 regulation of apoptosis. Science. 275:1132–1136,1997PubMedCrossRefGoogle Scholar
  139. 139.
    Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, and Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc. Natl. Acad. Sci. USA. 95:4997–5002, 1998CrossRefGoogle Scholar
  140. 140.
    Srinivasula SM, Ahmad M, Fernandes-Alnemri T, and Alnemri ES. Autoactivation of procaspase-9 by Apaf-1 -mediated oligomerization. Mol. Cell. 1:949–957,1998PubMedCrossRefGoogle Scholar
  141. 141.
    Reed JC. Cytochrome c-can’t live with it-can’t live without it. Cell. 91:559–562, 1997PubMedCrossRefGoogle Scholar
  142. 142.
    Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, and Moller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69:415–429,1993Google Scholar
  143. 143.
    Rouvier E, Luciani MF, and Goldstein P. Fas involvement in Ca2+-independent T cell-mediated cytotoxicity. J. Exp. Med. 177:195–200, 1993CrossRefGoogle Scholar
  144. 144.
    Arase H, Arase N, and Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. 181:1235–1238, 1995CrossRefGoogle Scholar
  145. 145.
    Russel JH. Activation-induced death o f mature T cell sin the regulation of immune responses. Curr. Opin. Immunol. 7:382–388, 1995CrossRefGoogle Scholar
  146. 146.
    Griffith TS, Brunner T, Fletcher SM, Green DR, and Gerguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1189–1191, 1995PubMedCrossRefGoogle Scholar
  147. 147.
    Schattner E, and Friedman SM. Fas expression and apoptosis in human B cells. Immunol Res. 15:246–257, 1996PubMedCrossRefGoogle Scholar
  148. 148.
    van Parijs L, and Abbas A. Role of Fas-mediated cell death in the regulation of immune responses. Curr. Opin. Immunol. 8:355–361, 1996CrossRefGoogle Scholar
  149. 149.
    Whiteside TL, and Rabinowich H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother. 46(4):175–184,1998PubMedCrossRefGoogle Scholar
  150. 150.
    Cardi G, Heaney JHA, Schned AR, and Ernstoff MS. Expression of Fas (APO-1 /CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res. 58:2078–2080, 1998PubMedGoogle Scholar
  151. 151.
    Zaks TZ, Chappell DB, Rosenberg SA, and Restifo NP. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J. Immunol. 162:3272–3279, 1999Google Scholar
  152. 152.
    Chappell DB, Zaks TZ, Rosenberg SA, and Restifo NP. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res. 59:59–62, 1999PubMedGoogle Scholar
  153. 153.
    Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, Huang H, Schulz J-13, Ohgaki H, Aguzzi A, Rammensee HG, and Weller M. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res. 62:2592–2599, 2002PubMedGoogle Scholar
  154. 154.
    Koyama S, Koike N, and Adachi S. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J. Cancer Res. Clin. Oncol. 128:73–79, 2002PubMedCrossRefGoogle Scholar
  155. 155.
    De Maria R, Lenti L, Malisan F, d’Agostino F, Tomassini B, Zeuner A, Rippo MR, and Testi R. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science. 277: 1652–1655,1997PubMedCrossRefGoogle Scholar
  156. 156.
    Kristal BS, and Brown AM. Apoptogenic ganglioside GD3 directly induces the mitochondrial permeability transition. J. Biol. Chem. 274:3169–3175, 1999Google Scholar
  157. 157.
    Mocellin S, Ohnmacht GA, Wang E, and Marincola FM. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int. J. Cancer. 93:236–242, 2001Google Scholar
  158. 158.
    Ronsin C, Chung-ScottV, Poullion I, Aknouche N, Gaudin C, and Triebel F A non-AUG-defined alternate open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J. Immunol. 163: 483–490,1999PubMedGoogle Scholar
  159. 159.
    Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, and Brugger W. Her-2/ neu-derived peptides are tumor associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58:732–736, 1998PubMedGoogle Scholar
  160. 160.
    Zhang XH, Takenaka I, Sato C, and Sakamoto H. p53 and HER-2 alterations in renal cell carcinoma. Urology 50:636–642, 1997PubMedCrossRefGoogle Scholar
  161. 161.
    Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, and Boon T.A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-Al by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1453–1457,1992CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Ithaar H. Derweesh
    • 1
    • 3
  • Charles S. Tannenbaum
    • 1
  • Patricia A. Rayman
    • 1
  • James H. Finke
    • 1
    • 2
    • 3
  1. 1.Department of ImmunologyLerner Research InstituteUSA
  2. 2.Experimental TherapeuticsUSA
  3. 3.Glickman Urological InstituteCleveland Clinic FoundationClevelandUSA

Personalised recommendations